These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36586583)

  • 1. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis.
    Leung DYM; Paller AS; Zaenglein AL; Tom WL; Ong PY; Venturanza ME; Kuligowski ME; Li Q; Gong X; Lee MS
    Ann Allergy Asthma Immunol; 2023 Apr; 130(4):500-507.e3. PubMed ID: 36586583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
    Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
    J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
    Gong X; Chen X; Kuligowski ME; Liu X; Liu X; Cimino E; McGee R; Yeleswaram S
    Am J Clin Dermatol; 2021 Jul; 22(4):555-566. PubMed ID: 33982267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
    Bloudek L; Eichenfield LF; Silverberg JI; Joish VN; Lofland JH; Sun K; Augustin M; Migliaccio-Walle K; Sullivan SD
    Am J Clin Dermatol; 2023 Jan; 24(1):109-117. PubMed ID: 36264430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies.
    Simpson EL; Bissonnette R; Chiesa Fuxench ZC; Kallender H; Sturm D; Ren H; Stein Gold LF
    J Dermatolog Treat; 2024 Dec; 35(1):2310633. PubMed ID: 38297490
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
    Blauvelt A; Kallender H; Sturm D; Li Q; Ren H; Eichenfield LF
    Dermatol Ther (Heidelb); 2024 Nov; 14(11):3161-3174. PubMed ID: 39375281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
    Blauvelt A; Kircik L; Papp KA; Simpson EL; Silverberg JI; Kim BS; Kwatra SG; Kuligowski ME; Venturanza ME; Wei S; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):137-146. PubMed ID: 36066323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Forman SB; Kuligowski ME; Kallender H; Sun K; Ren H; Simpson EL
    J Am Acad Dermatol; 2023 May; 88(5):1008-1016. PubMed ID: 36574595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Sturm D; Wang M; Eichenfield LF
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2139-2151. PubMed ID: 38995504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
    J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.